P450-dependent enzymes as targets for prostate cancer therapy

Journal of Steroid Biochemistry and Molecular Biology

Volumn 56, Issue 1-6, 1996, Pages 133-143

  De Coster, R ^a   Wouters, W ^a   Bruynseels, J ^a  

^a JANSSEN RESEARCH FOUNDATION   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ABIRATERONE; AMINOGLUTETHIMIDE; AROMATASE; CYTOCHROME P450; FORMESTANE; HYDROCORTISONE; KETOCONAZOLE; LIAROZOLE FUMARATE; RETINOIC ACID; STEROID 17,20 LYASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; CONFERENCE PAPER; CONTROLLED STUDY; DRUG TARGETING; GASTROINTESTINAL DISEASE; HUMAN; HUMAN CELL; MALE; NONHUMAN; PROSTATE CANCER; RAT;

ANIMALIA; LIA; MINK CELL FOCUS-FORMING VIRUS;

EID: 0029871514     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/0960-0760(95)00230-8     Document Type: Conference Paper

References (101)

1. Boring C. C., Squires T. S. and Tong T.: Cancer statistics CA. Cancer J. Clin. 43 (1993) 7-36.
2. Denis L. J.: Controversies in the management of localised and metastatic prostatic cancer. Eur. J. Cancer 27 (1991) 333-341.
3. Porter T. J. and Coon M. J.: Cytochrome P450. Multiplicity of isoforms, substrates and catalytic and regulatory mechanisms. J. Biol. Chem. 266 (1991) 13,469-13,472.
4. Vanden Bossche H., Marichal P., Willemsens G. and Janssen P. A. J.: Effects of inhibitors of the P450-dependent metabolism of endogenous compounds in fungi, plants and vertebrates. In Molecular Aspects of Monooxygenases and Bioactivation of toxic compounds (Edited by E. Arinç, J. B. Schenkman and E. Hodgson). Plenum Press, New York (1991) pp. 345-363.
5. Vanden Bossche H., Koymans L. and Moereels H.: P450 inhibitors of use in medical treatment: focus on mechanism of action. Pharmac. Ther. 57 (1995) 79-100.
6. Vanden Bossche H., Moereels H. and Koymans L. M. H.: Aromatase inhibitors - mechanisms for non-steroidal inhibitors. Breast Cancer Res. Treat. 30 (1994) 43-55.
7. Goss P. E. and Gwyn K. M. E. H.: Current perspectives on aromatase inhibitors in breast cancer. J. Clin. Oncol. 12 (1994) 2460-2470.
8. Chung B.-C., Picado-Leonard J., Haniu M., Bienkowski M., Hall P. F., Shively J. F. and Miller W. L.: Cytochrome P450 c17 (steroid 17α-hydroxylase/17,20-lyase): cloning of human adrenal and testicular cDNAs indicates the same gene is expressed in both tissues. Proc. Natn. Acad. Sci. U.S.A. 84 (1987) 407-411.
9. Bradshaw K. D., Waterman M. R., Couch R. T., Simpson E. R. and Zuber M. X.: Characterization of complementary deoxyribonucleic acid for human adrenocortical 17α-hydroxylase: probe for analysis of 17α-hydroxylase deficiency. Molec. Endocr. 1 (1987) 348-354.
10. 5-lyase activity of rat CYP17. J. Biol. Chem. 268 (1993) 18,267-18,271.
11. Lin D., Zhang L. H., Chiao E. and Miller W. L.: Modelling and mutagenisis of the active site of human P450c17. Molec. Endocr. 8 (1994) 392-402.
12. De Felice R., Johnson D. G. and Galgiani S. H.: Gynecomastia with ketoconazole. Antimicrob. Agents Chemother. 19 (1981) 1073-1074.
13. Pont A., Williams P. L., Azhar S., Reitz R. E., Bochra C., Smith E. R. and Stevens ?.: Ketoconazole blocks testosterone biosynthesis. Arch. Intern. Med. 142 (1982) 2137-2140.
14. Santen R. J., Vanden Bossche H., Symoens J., Brugmans J. and De Coster R.: Site of action of low dose ketoconazole on androgen biosynthesis in man. J. Clin. Endocr. Metab. 57 (1983) 732-736.
15. Kan P. B., Hirst M. A. and Feldman D.: Inhibition of steroidogenic cytochrome P450 enzymes in rat testis by ketoconazole and related imidazole antifungal drugs. J. Steroid Biochem. 23 (1985) 1023-1029.
16. Ayub M. and Levell M. J.: Inhibition of testicular 17α-hydroxylase and 17,20-lyase but not 3β-hydroxysteroid-deshydrogenase-isomerase or 17β-hydroxysteroid oxidoreductase by ketoconazole and other imidazole drugs. J. Steroid. Biochem. 28 (1987) 521-531.
17. Vanden Bossche H.: Inhibitors of P450-dependent steroid biosynthesis: from research to medical treatment. J. Steroid Biochem. olec. Biol. 43 (1992) 1003-1021.
18. Lambert A., Mitchell R. and Robertson W. R.: The effect of ketoconazole on adrenal and testicular steroidogenesis in vitro. Biochem. Pharmacol. 35 (1986) 3999-4004.
19. De Coster R., Coene M.-C., Van Camp C., Van Camp K., Beerens D. and Cools W.: Comparative effects of ketoconazole in rat, dog and human testicular steroidogenesis. J. Enzyme Inhibition 2 (1989) 261-268.
20. Sikka S. C., Swerdloff R. S. and Rajfer J.: In vitro inhibition of testosterone biosynthesis by ketoconazole. Endocrinology 116 (1985) 1920-1925.
21. Couch R. M., Muller J., Perry Y. S. and Winter J. S. D.: Kinetic analysis of inhibition of human adrenal steroidogenesis by ketoconazole. J. Clin. Endocr. Met. 65 (1987) 551-554.
22. Ayub M. and Levell M. J.: Inhibition of human adrenal steroidogenic enzymes in vitro by imidazole drugs including ketoconazole. J. Steroid Biochem. 32 (1989) 515-524.
23. Engelhardt D., Weber M. M., Miksch T., Abedinpour F. and Jaspers C.: The influence of ketoconazole on human adrenal steroidogenesis: incubation studies with tissue slices. Clin. Endocr. 35 (1991) 163-168.
24. Weber M. M., Luppa P. and Engelhardt ?.: Inhibition of human adrenal androgen secretion by ketoconazole. Klin. Wochenschr. 67 (1989) 707-712.
25. De Coster R., Caers I., Coene M.-C., Amery W., Beerens D. and Haelterman C.: Effects of high dose ketoconazole therapy on the main testicular and adrenal steroids in previously untreated prostatic cancer patients. Clin. Endocr. 24 (1986) 657-664.
26. Trachtenberg J. and Zadra J.: Steroid synthesis inhibition by ketoconazole: sites of action. Clin. Invest. Med. 11 (1988) 1-5.
27. De Coster R., Mahler C., Denis L., Coene M.-C., Caers I., Amery W., Hochterman C. and Beerens D.: Effects of high-dose ketoconazole and dexamethasone on ACTH-stimulated adrenal steroidogenesis in orchiectomized prostatic cancer patients. Acta Endocr. 115 (1987) 265-271.
28. Pont A., Graybill J. R., Craven P. C., Galgiani J. H., Dismukes W. E., Reitz R. E. and Stevens D. A.: High dose ketoconazole therapy and adrenal and testicular function in humans. Arch. Intern. Med. 144 (1985) 2150-2153.
29. Heyns W., Drochmans W., van der Schueren E. and Verhoeven G.: Endocrine effects of high-dose ketoconazole therapy in advanced prostatic cancer. Acta Endocr. 110 (1985) 276-283.
30. Trachtenberg J.: Ketoconazole therapy in advanced prostatic cancer. J. Urol. 132 (1984) 61-64.
31. Amery W. K., De Coster R. and Caers I.: Ketoconazole: from an antimycotic to a drug for prostate cancer. Drug Dev. Res. 8 (1986) 299-307.
32. Mahler C., Verhelst J. and Denis L.: Ketoconazole and liarozole in the treatment of advanced prostatic cancer. Cancer 71 (1993) 1068-1073.
33. Jubelirer S. J. and Hogan T.: High dose ketoconazole for the treatment of hormone refractory metastatic prostate carcinoma: 16 cases and a review of the literature. J. Urol. 142 (1989) 89-94.
34. Lowe F. C. and Bamberger M. H.: Indication for use of ketoconazole in management of metastatic prostate cancer. Urochemotherapy 6 (1990) 541-545.
35. Bruynseels J., De Coster R., Van Rooy Patsy, Wouters W., Coene M.-C., Snoeck E., Raeymaekers A., Freyne E., Sanz G., Vanden Bussche G., Vanden Bossche H., Willemsen G. and Janssen P. A. J.: R 75251, a new inhibitor of steroid biosynthesis. Prostate 16 (1990) 345-347.
36. Barrie S. E., Potter G. A., Goddard P. M., Hayns B. P., Dowsett M. and Jarman M.: Pharmacology of novel steroidal inhibitors of cytochrome P45017α (17α-hydroxylase/ C17-20 lyase). J. Steroid Biochem. Molec. Biol. 50 (1994) 267-273.
37. Haynes B. P., Houghton J., King N., Barrie S. E., Potter G. A., Griggs L. J., Dowsett M. and Jarman M.: Pharmacology of CB 7598, a highly potent inhibitor of cytochrome P450 c17. Cancer Res. 35 (1994) 420.
38. Li J., Li Y., Son C., Banks P. and Brodie A. M. H.: 4-pregnen-3-one-20β-carboxaldehyde: a potent inhibitor of 17α-hydroxylase/C17,20-lyase and 5α-reductase. J. Steroid Biochem. Molec. Biol. 42 (1992) 265-275.
39. Li J. S., Li Y., Son C. and Brodie A. M. H.: Inhibition of androgen synthesis by 22-hydroximino-23,24-bisnor-4-cholen-3-one. Prostate 26 (1995) 140-150.
40. Neubauer B. L., Best K. L., Blohm T. R., Gates C. G., Goode R. L., Hirsch K. S., Leughlin M. E., Petrow V., Smalstig E. B., Stamm N. B., Toomey R. E. and Hoover D. M.: LY207320 (6-methylene-4-pregnene-3,20-dione) inhibits testosterone biosynthesis, androgen uptake, 5α-reductase, and produces prostatic regression in male rats. Prostate 23 (1993) 181-199.
41. Angelastro M. R., Laughlin M. E., Schatzman G. L., Bey P. and Blohm T. R.: 17β-(cyclopropylamine)-andro-5-en-3β-ol, a selective mechanism based inhibitor of cytochrome P45017α (steroid 17α-hydroxylase/C17,20-lyase) Biochem. Biophys. Res. Commun. 162 (1989) 1571-1577.
42. Jarman M., Barrie S. E., Deadman J. J., Houghton J. and McCague R.: Hydroxyperfluoroazobenzenes: novel inhibitors of enzymes of androgen biosynthesis. J. Med. Chem. 33 (1990) 2452-2455.
43. McCague R., Rowlands M. G., Barrie S. E. and Houghton J.: Inhibition of enzymes of estrogen and androgen biosynthesis by esters of 4-pyridylacetic acid. J. Med. Chem. 33 (1990) 3050-3055.
44. Laughton C. A. and Neidle S.: Inhibitors of the P450 enzymes aromatase and lyase. Cristallographic and molecular modeling studies suggest structural features of pyridylacetic and derivatives responsible for differences in enzyme inhibitory activity. J. Med. Chem. 33 (1990) 3055-3060.
45. Mahler C. and Denis L.: Management of relapsing disease in prostate cancer. Cancer B (1992) 329-334.
46. Geller J.: Basis for hormonal management of advanced prostate cancer. Cancer 71 (1993) 1639-1645.
47. Santen R. J., Samojlik E. and Worgul T. J.: Aminoglutethimide. Scientific profile. In A Comprehensive Guide to the Therapeutic use of Aminoglutethimide (Edited by R. J. Santen and I. C. Henderson). Karger Press, Basel (1982) pp. 101-164.
48. Stanford E., Drago J., Rohnes T., Santen R. and Lipton A.: Aminoglutethimide medical adrenalectomy for advanced prostatic cancer. J. Urol. 115 (1976) 170-174.
49. Murray R. and Pitt B.: Aminoglutethimide in the treatment of advanced prostatic cancer. In Prostate Cancer: Part A. Research, endocrine treatment and histopathology. (Edited by G. P. Murphy, S. Khoury, R. Kuss, C. Chatelain and L. Denis). Alan R. Liss, New York (1987) pp. 275-282.
50. Chang A. Y. C., Bennett J. M., Pandya K. J., Asbury R. and McCune C.: A study of aminoglutethimide and hydrocortisone in patients with advanced and refractory prostate carcinoma. Am. J. Clin. Oncol. 12 (1989) 358-360.
51. Sartor O., Cooper M., Weinberger M., Headlee D., Thibault A., Tompkins A., Steinberg S., Figg W. D., Linehan W. M. and Meyers C. E.: Surprising activity of flutamide withdrawal when combined with aminoglutethimide in treatment of "hormone refractory" prostate cancer. J. Natn. Cancer Inst. 86 (1984) 222-227.
52. Plowman P. H., Perry L. A. and Charod T.: Androgen suppression by hydrocortisone without aminoglutethimide in orchiectomised men with prostatic cancer. Br. J. Urol. 59 (1987) 255-257.
53. Dowsett M., Shearer R. J., Ponder B. A. J., Malone P. and Jeffcoate S. L.: The effects of aminoglutethimide and hydro-cortisone, alone and combined, on androgen levels in post-orchidectomy prostatic cancer. Br. J. Cancer 57 (1988) 190-192.
54. Kuburagi Y., Marino M. B., Kirdani R. Y., Greco J. P., Karr J. P. and Strandberg A. A.: The possibility of aromatization of androgen in human prostate. J. Steroid Biochem. 26 (1987) 739-742.
55. Karr J. P., Kaburagi Y., Mann C. F. and Sandberg A. A.: The potential significance of aromatase in the ethiology and treatment of prostatic disease. Steroids 50 (1987) 451-457.
56. Bélanger C., Veilleux R. and Labrie F.: Stimulatory effects of androgens, estrogens, progestins and dexamethasone on the growth of the LNCaP human prostate cancer cells. Ann. NY Acad. Sci. 595 (1998) 399-402.
57. Nakhla A. M., Khan M. S., Romas N. P. and Rosner W.: Estradiol causes the rapid accumulation of cAMP in human prostate. Proc. Natn. Acad. Sci. U.S.A. 91 (1994) 5402-5406.
58. Smith T., Chrisholm G. D. and Habib F. K.: Failure of human benign prostatic hyperplasia to aromatase testosterone. J. Steroid Biochem. 17 (1982) 119-120.
59. Castagnetta L. A., Miceli M. D., Sorci C. M. G., Pfeffer V., Farrugio R., Oliveri G., Calabro M. and Carruta G.: Growth of LNCaP human prostate cancer cells is stimulated by estradiol via its own receptor. Endocrinology 136 (1995) 2309-2319.
60. Sinowatz F., Amselgruber W., Plendl J., Kolle S., Neumuller Ch. and Boos G.: Effects of hormones on the prostate in adult and aging men and animals. Microsc. Res. Technique 30 (1995) 282-292.
61. Brodie A. M. H., King D. A., Meyer K. M. and Inkster S. E.: Lack of evidence for aromatase in human prostatic tissues: effects of 4-hydroxyandrostenedione and other inhibitors on androgen metabolism. Cancer Res. 49 (1989) 6551-6555.
62. Ayub M. and Levell M. J.: The inhibition of human prostatic aromatase activity by imidazole drugs including ketoconazole and 4-hydroxyandrostenedione. Biochem. Pharmacol. 40 (1990) 1569-1575.
63. Davies J. H., Rowlands M. G., Dowsett M., Coombes R. D. and Shearer R. J.: In vitro studies of the effect of 4-OHA on androgen metabolism in human benign and malignant prostatic tissue. Cancer Res. 31 (1990) 303.
64. Henderson D., Habenicht U.-F., Mishino Y. and El Etreby M. F.: Estrogen and benign prostatic hyperplasia. The basis for aromatase therapy. Steroids 50 (1987) 219-223.
65. Habenicht U. F.: Aromatase inhibitors and benign prostatic hyperplasia: chance and limitation. In Sex Hormones and Anti-hormones in Endocrine Dependent Pathology: Basic and Clinical Aspects (Edited by M. Serio). Elsevier, Amsterdam (1994) pp. 125-135.
66. Shearer R. J., Davies J. H., Dowsett M., Malone P. R., Hedley A., Cunningham D. and Coombes R. D.: Aromatase inhibition in advanced prostatic cancer: preliminary communication. Br. J. Cancer 62 (1990) 275-276.
67. Davies J. H., Dowsett M., Jacobs S., Coombes R. D., Hedley A. and Shearer R. J.: Aromatase inhibition: 4-hydroxy-androstenedione (4-OHA, CGP32349) in advanced prostatic cancer. Br. J. Cancer 66 (1992) 139-142.
68. Purohit A., Flanagan A. M. and Reed M. J.: Estrogen synthesis by osteoblast cell lines. J. Clin. Endocr. Metab. 61 (1992) 152-157.
69. Tanaka S., Haji M., Nishi Y., Yanasi T., Takayanagi R. and Nawata. Aromatase activity in osteoblast-like osteosarcoma cell. Calcif. Tissue Int. 52 (1993) 107-109.
70. Lotan R.: Mechanism of action of retinoids. Cancer Bull. 38 (1986) 113-116.
71. Blanner W. S. and Olson J. A.: Retinoid and retinoic acid metabolism. In The Retinoids Biology, Chemistry and Medicine, 2nd Edition (Edited by M. B. Sporn, A. B. Roberts and D. S. Goodman). Raven Press, New York (1994) pp. 229-256.
72. Hong W. K. and Itri L. M.: Retinoids and human cancer. In The Retinoids Biology, Chemistry and Medicine, 2nd Edition (Edited by M. B. Sporn, A. B. Roberts and D. S. Goodman). Raven Press, New York (1994) pp. 597-630.
73. Fong G. J., Sutkowski D. M., Braun E. J., Bauer K. D., Sherwood E. R., Lee C. and Kozlowski J. M.: Effects of retinoic acid on the proliferation and secretory activity of androgen-responsive prostatic carcinoma cells. J. Urol. 149 (1993) 1190-1194.
74. Dahiya R., Park H. D., Cusick J., Versella R. L., Fournier G. and Narayan P.: Inhibition of tumorigenic potential and prostate-specific antigen expression in LNCaP human prostate cancer cell line by 13-cis-retinoic acid. Int. J. Cancer 59 (1994) 126-132.
75. Young C. Y. F., Murtha P. E., Andrews P. E., Lindzey J. K. and Tindall D. J.: Antagonism of androgen action in prostate tumor cells by retinoic acid. Prostate 25 (1994) 39-45.
76. Peehl D. M., Wong S. T. and Stamey T. A.: Vitamin A regulates proliferation and differentiation of human prostatic epithelial cells. Prostate 23 (1993) 69-78.
77. Brandes D.: Retinoic acid receptor and surface markers.: In The Prostatic Cell: Structure and Function (Edited by G. P. Murphy, A. A. Sandberg and J. P. Kerr). Alan R. Liss, New York (1981) p. 207.
78. de The M., Marchio A., Tiollais P. and Dejean A.: Differential expression and ligand regulation of the retinoic acid receptor a and β genes. EMBO J. 8 (1989) 429-433.
79. Krekels M. D. W. G., Zimmerman J., Janssens B., Van Ginckel R., Cools W., Van Hove C., Coene M.-C. and Wouters W.: Comparative analysis of the oxidative metabolism of retinoic acid and its inhibition by liarozole fumarate in rat liver and in rat Dunning R3327G prostate tumor tissue. Prostate 27 (1996).
80. Lanitzki I. and Goodman D. S.: Inhibition of the effects of methylcholanthrene on mouse prostate in organ culture by vitamin A and its analogs. Cancer Res. 34 (1974) 1567-1571.
81. Chopra D. P. and Wilkoff L. J.: Reversal by vitamin A analogues (retinoids) of hyperplasia induced by N-methyl-N'-nitro-N-nitroguanidine in mouse prostate organ cultures. J. Natn. Cancer Inst. 58 (1977) 923-930.
82. Pienta K. J., Nguyet N. M. and Lehr J. E.: Treatment of prostate cancer in the rat with the synthetic retinoid fenretinide. Cancer Res. 53 (1993) 224-226.
83. Pollard M., Luckert P. H. and Sporn M. B.: Prevention of primary prostate cancer in Lobund-Wistar rats by N-(4-hydroxyphenyl)retinamide. Cancer Res. 51 (1991) 3610-3611.
84. Slawin K., Kadman D., Park S. H., Scardino P. T., Anzano M., Sporn M. B. and Thompson T. C.: Dietary fenretinide, a synthetic retinoid, decreases the tumor incidence and the tumor mass of ras-myc-induced carcinomas in the mouse prostate reconstitution model system. Cancer Res. 53 (1993) 4461-4465.
85. Carter B. S., Carter B. and Isaacs J. T.: Epidemiologic evidence regarding predisposing factors to prostate cancer. Prostate 16 (1990) 187-197.
86. Trump D. L.: Retinoids in bladder, testis and prostate cancer: epidemiologic, preclinical and clinical observations. Leukemia 8 (1994) 550-554.
87. Trump D. L., Smith D., Stiff D., Adedoyin A., Bahnson R., Day R. and Branch R.: All-trans retinoic acid (ATRA) in hormone refractory prostate cancer (HRPC): ineffectiveness due to failure of drug delivery? Proc. Am. Soc. Clin. Oncol. 751 (1994) 241.
88. Wouters W., Van Dun J., Dillen A., Coene M.-C., Cools W. and De Coster R.: Effects of liarozole, a new antitumoral compound on retinoic acid-induced inhibition of cell growth and on retinoic acid metabolism in MCF-7 human breast cancer cells. Cancer Res. 52 (1992) 2841-2846.
89. Van Wauwe J., Van Nyen G., Coene M.-C., Stoppie P., Cools W., Goossens J., Borghgraef P. and Janssen P. A. J.: Liarozole, an inhibitor of retinoic acid metabolism, exerts retinoid-mimetic effects in vivo. J. Pharmacol Exp. Ther. 261 (1992) 773-779.
90. Van Wauwe J., Coene M.-C., Cools W., Goossens J., Lauwers W., Le Jeune L., Van Hove C. and Van Nyen G.: Liarozole fumarate inhibits the metabolism of 4-keto-all-trans-retinoic acid. Biochem. Pharmacol. 47 (1994) 737-741.
91. Van heusden J., Xhonneux B., Wouters W., Borgers M., Ramaekers F. C. S., De Coster R. and Smets G.: Effects of liarozole, an antitumor drug, on structural remodelling of human breast carcinoma MCF-7 cells in vitro. Eur. J. Cell Biol. 5 (Suppl) (1995) 95.
92. Van Wauwe J. P., Coene M.-C., Goossens J., Cools W. and Montbaliu J.: Effects of cytochrome P450 inhibitors on the in vivo metabolism of all-trans-retinoic acid in rats. J. Pharmacol. Exp. Ther. 252 (1990) 365-369.
93. Achkar C. C., Bentel J. M., Boylan J. F., Scher H. I., Gudas L. J. and Miller W. H.: Differences in the pharmacokinetic properties of orally administered all-trans-retinoic acid and 9-cis-retinoic acid in the plasma of nude mice. Drug. Metab. Disp. 22 (1994) 451-458.
94. Smets G., Van Ginckel R., Daneels G., Moeremans M., Van Wauwe J., Coene M.-C., Ramaekers F. C. S., Schalken J. A., Borgers M. and De Coster R.: Liarozole, an antitumor drug, modulates cytokeratin expression in the Dunning AT-6sq prostatic carcinoma through in situ accumulation of all-trans-retinoic acid. Prostate 27 (1995) 129-140.
95. Westarp M. E., Westarp M. P., Bruynseels J., Bollag W. and Kornhuber H. H.: Oral liarozole as a catabolic inhibitor potently increases retinoic acid in vivo: First experience from an ongoing therapeutic trial in highly malignant primary brain tumors. Onkologie 16 (1993) 22-25.
96. Miller V. A., Rigas J. R., Muindi J. R. F., Tong W. P., Venkatraman E., Kris M. G. and Warrell R. P., Jr.: Modulation of all-trans-retinoic acid pharmacokinetics by liarozole. Cancer Chemother. Pharmacol. 34 (1994) 522-526.
97. Van Ginckel R., De Coster R., Wouters W., Van Der Veer R., Goeminne N., Jagers E., Van Cauteren H., Wouters L., Distelmans W. and Janssen P. A. J.: Antitumoral effects of R75251 on the growth of transplantable R3372 prostatic adenocarcinoma in rats. Prostate 16 (1990) 313-323.
98. Stearns M. E., Wang M., Fudge K.: Liarozole and 13-cis-retinoic acid antiprostatic tumor activity. Cancer Res. 53 (1993) 3073-3077.
99. Dijkman A., Van Moorsselaar R. J. A., Van Ginckel R., Van Stratum P., Wouters W., Schalken F. M. J. and De Coster R.: Antitumoral effects of liarozole in androgen-dependent and -independent R3327Dunning prostate adenocarcinomas. J. Urol. 151 (1994) 217-222.
100. Mahler C., Verhelst J., Denis L., De Porre P., De Coster R. and Bruynseels J.: Liarozole fumarate. Drugs Future 19 (1994) 552-556.
101. Boccardo F., Cannata D., Guarneri D., Oneto F., Cortesi E. and Bono A.: R75251 in prostate cancer patients in progression after first-line hormonal treatment. Tumori 80 (1994) 276-279.